Literature DB >> 8649842

The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas.

P J Biggs1, P Chapman, S R Lakhani, J Burn, M R Stratton.   

Abstract

Hereditary cylindromatosis is a rare autosomal dominant disease characterised by the development of multiple benign neoplasms of the skin. We recently localised the gene responsible for this disease (cyld1) to chromosome 16q12-q13 and provided evidence that it is a tumour suppressor gene (Biggs et al., 1995). We have now examined polymorphic markers on every chromosome, some of which are close to known tumour suppressor genes, in 25 tumours from 4 individuals with familial cylindromatosis. No loss of heterozygosity (LOH) was detected other than at loci on chromosome 16q. This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas. We have also demonstrated LOH using markers on chromosome 16q in 8/14 (57%) sporadic cylindromas, indicating that the cyld1 gene is likely to be involved in the genesis of both familial and sporadic cylindromas.

Entities:  

Mesh:

Year:  1996        PMID: 8649842

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Two hits revisited again.

Authors:  I P Tomlinson; R Roylance; R S Houlston
Journal:  J Med Genet       Date:  2001-02       Impact factor: 6.318

2.  Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Authors:  Yingai Jane Jin; Sally Wang; Joshua Cho; M Angelica Selim; Tim Wright; George Mosialos; Jennifer Y Zhang
Journal:  JCI Insight       Date:  2016-07-21

3.  Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours.

Authors:  N Leonard; R Chaggar; C Jones; M Takahashi; A Nikitopoulou; S R Lakhani
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

4.  CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Authors:  Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-08

5.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

6.  Familial cylindromatosis mimicking tuberous sclerosis complex and confirmation of the cylindromatosis locus, CYLD1, in a large family.

Authors:  S Verhoef; C T Schrander-Stumpel; V D Vuzevski; A Tempelaars; L A Jansen; G A Malfeyt; T L Ceelen; D Lindhout; D J Halley; A M van den Ouweland
Journal:  J Med Genet       Date:  1998-10       Impact factor: 6.318

Review 7.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

8.  Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Roy Lamping; Raoul van de Graaf; Monique M van Veghel-Plandsoen; S M Franken; A C Houweling
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

9.  The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.

Authors:  Alexandre Regamey; Daniel Hohl; Jia Wei Liu; Thierry Roger; Priit Kogerman; Rune Toftgard; Marcel Huber
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD.

Authors:  Nadine Hövelmeyer; F Thomas Wunderlich; Ramin Massoumi; Charlotte G Jakobsen; Jian Song; Marcus A Wörns; Carsten Merkwirth; Andrew Kovalenko; Monique Aumailley; Dennis Strand; Jens C Brüning; Peter R Galle; David Wallach; Reinhard Fässler; Ari Waisman
Journal:  J Exp Med       Date:  2007-10-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.